Gonadotropin-Releasing Hormone Analogs and Antagonists — CPB 0501 | AETNA Coverage Update

Aetna modified CPB 0501 covering GnRH analogs and antagonists, effective December 20, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0501 governing gonadotropin-releasing hormone (GnRH) analogs and antagonists across commercial medical plans. This coverage policy affects a wide range of HCPCS codes — including J1950, J1951, J9155, J9202, J9217, J9218, J9219, J9226, J3315, and J3316 — used for prostate cancer, endometriosis, ART, gender dysphoria, and several other indications. If your practice bills any of these codes to Aetna, read this before your next claim goes out.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Gonadotropin-Releasing Hormone Analogs and Antagonists
Policy Code	CPB 0501
Change Type	Modified
Effective Date	December 20, 2025
Impact Level	High
Specialties Affected	Oncology, urology, reproductive endocrinology, OB/GYN, pediatric endocrinology, adolescent medicine
Key Action	Review precertification requirements for prostate cancer indications and update authorization workflows for all GnRH agent billing before December 20, 2025

---

Aetna GnRH Analog and Antagonist Coverage Criteria and Medical Necessity Requirements 2025

The Aetna GnRH analog coverage policy under CPB 0501 draws hard lines between covered and non-covered indications. Medical necessity criteria vary by drug — so a blanket understanding of "GnRH agents are covered" will get you denied.

Prostate cancer — precertification required. This is the most operationally demanding part of the policy. Aetna requires prior authorization for all GnRH products used for prostate cancer. Call (866) 752-7021 or fax the Statement of Medical Necessity form to (888) 267-3277. Missing this step guarantees a claim denial — there's no grace period.

Cetrorelix acetate and ganirelix acetate (S0132). Aetna considers these medically necessary only for inhibition of premature LH surges during ovulation induction or assisted reproductive technology (ART). That's it. Every other indication is experimental or unproven. Coverage of these GnRH antagonists is also plan-dependent — it's limited to plans that cover advanced reproductive technologies. Check benefit plan descriptions before submitting.

Degarelix (Firmagon, J9155). Covered for prostate cancer treatment only. For reauthorization, the member must show clinical benefit — serum testosterone below 50 ng/dL is the example Aetna cites — and must not have experienced unacceptable toxicity. Document that lab value before you submit for continuation.

Goserelin acetate (Zoladex, J9202). This drug has the broadest covered indication list in the policy, including breast cancer, endometriosis, endometrial thinning before ablation, and gender dysphoria — among others. The policy summary provided is partial; verify the complete indication list for goserelin in the full CPB 0501 document before billing J9202 for indications not explicitly confirmed here. The 10.8 mg strength is only covered for prostate cancer, breast cancer, and gender dysphoria. Bill the 10.8 mg dose for anything outside those three and you're billing into a denial.

Leuprolide acetate (billed across J1950, J1951, J1952, J1954, J9217, J9218, J9219) carries similarly tiered criteria. The policy summary provided is partial; verify the complete indication list and which leuprolide formulations map to which indications in the full CPB 0501 document. Do not assume a specific J-code applies to a specific indication without confirming it in the full policy.

Histrelin (Supprelin LA, J9226). Covered for central precocious puberty and gender dysphoria with specific clinical criteria. For gender dysphoria in members under 18, the prescribing provider must be specialized in transgender youth care — pediatric endocrinology, OB/GYN, or family/internal medicine — and must have collaborated with a mental health provider.

Triptorelin (J3315, J3316). Covered for prostate cancer, endometriosis, central precocious puberty, and gender dysphoria. Prior authorization requirements follow the same structure as other GnRH analogs under this policy. Verify the complete indication list in the full CPB 0501 document.

The reimbursement picture is also complicated by plan design. ART-related coverage for cetrorelix and ganirelix only applies when the member's plan includes advanced reproductive technology benefits. Verify this before you submit S0132 claims.

---

Aetna GnRH Analog Exclusions and Non-Covered Indications

Several indications are explicitly not covered under CPB 0501. Flag these in your charge capture now.

Goserelin 10.8 mg for non-specified diagnoses. The 10.8 mg Zoladex implant is not covered for any diagnosis outside prostate cancer, breast cancer, and gender dysphoria. If a provider orders the 10.8 mg strength for endometriosis or another gynecologic indication, that's a denial.

Cetrorelix and ganirelix for off-label indications. Any use outside LH surge suppression for ovulation induction or ART is experimental, investigational, or unproven per Aetna's coverage policy. No exceptions are listed.

Degarelix for non-prostate-cancer indications. Same rule — anything beyond prostate cancer treatment is considered experimental or unproven.

Gender dysphoria without proper prescriber collaboration is also a coverage risk. For members under 18, the prescriber must be specialized in transgender youth care and must have coordinated with a mental health provider. Missing that documentation means a likely denial.

---

Coverage Indications at a Glance

---

Aetna GnRH Analog Billing Guidelines and Action Items 2025

GnRH analog billing under this updated CPB 0501 has real teeth. The precertification requirement for prostate cancer, the plan-level ART restriction, and the prescriber-specialty rules for gender dysphoria are all active denial triggers. Here's what to do before the December 20, 2025 effective date.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for GnRH Analogs Under CPB 0501

Covered HCPCS Codes (When Selection Criteria Are Met)

Additional HCPCS Codes Referenced in Policy

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
11980	CPT	Subcutaneous hormone pellet implantation (implantation of estradiol and/or testosterone pellets)

ICD-10-CM Diagnosis Codes

CPB 0501 references 551 ICD-10-CM codes. The full list is too extensive to reproduce here. Verify applicable diagnosis codes directly in the full policy at app.payerpolicy.org/p/aetna/0501.

The following diagnostic categories are confirmed in the policy source data:

Do not use this table as your complete diagnosis code reference. Pull the full 551-code list from the policy before submitting claims.

---